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and Dose–Response Meta-analysis A  C




Acrylamide is a probable human carcinogen. Aside from occu-
pational exposures and smoking, diet is themain source of exposure
in humans. We performed a systematic review of the association
between estimated dietary intake of acrylamide and risk of female
breast, endometrial, and ovarian cancers in nonexperimental stud-
ies published through February 25, 2020, and conducted a dose–
response meta-analysis. We identified 18 papers covering 10 dif-
ferent study populations: 16 cohort and two case–control studies.
Acrylamide intake was associated with a slightly increased risk of
ovarian cancer, particularly among never smokers. For endometrial
cancer, risk was highest at intermediate levels of exposure, whereas
the association was more linear and positive among never
smokers. For breast cancer, we found evidence of a null or
inverse relation between exposure and risk, particularly among
never smokers and postmenopausal women. In a subgroup
analysis limited to premenopausal women, breast cancer risk
increased linearly with acrylamide intake starting at 20 mg/day of
intake. High acrylamide intake was associated with increased
risks of ovarian and endometrial cancers in a relatively linear
manner, especially among never smokers. Conversely, little
association was observed between acrylamide intake and breast
cancer risk, with the exception of premenopausal women.
Introduction
Acrylamide is an organic industrial chemical that is white, odorless,
and crystalline in structure. It has been available commercially since
themid-1950s, and is used primarily in paper and plastic production as
a flocculating agent to purify drinking water and wastewater, and as a
sealing agent in buildings (1). In 1994, International Agency for
Research on Cancer classified acrylamide as a probable human car-
cinogen (2A) based on animal experiments, considering exposure
mainly from occupational and tobacco sources (2, 3). Only in 2002,
Tareke and colleagues demonstrated the presence of acrylamide in
foods and the importance of cooking technique in the formation of
acrylamide (4). The main chemical process involved in acrylamide
production is known as the “Maillard reaction” (5). In particular,
acrylamide occurs naturally in starchy foods during cooking processes
at high temperatures such as frying, baking, and grilling, even during
industrial transformation processes at over 120Cand at lowhumidity.
Conversely, boiling and steaming do not typically form acrylamide.
Acrylamide is formed from sugars and proteins with high content of
asparagine, an amino acid that is naturally present in many foods,
especially potatoes, grain products, and coffee (5, 6). In contrast, meat,
dairy, and seafood products have lower acrylamide content (6). In
adults, foods that contribute most to dietary intake of acrylamide
include French fries, potato chips, biscuits, and coffee (7, 8). On the
basis of their usual serving size (9, 10) and according to acrylamide
survey data in food (11), a standard portion of French fries (70 g)
accounts for 30 mg/day of acrylamide, potato chips (27 g) for around
11 mg/day, while coffee (355 g) and biscuits (57 g) for about 4 and
3 mg/day, respectively.
Although acrylamide has been shown to have carcinogenic, neu-
rotoxic, and adverse reproductive effects in animal models (12, 13),
evidence of its health effects in humans is scarce and inconsistent.
Occupational studies have shown adverse effects on both the periph-
eral and central nervous system after acute exposure, mainly via
inhalation of high doses of acrylamide ranging from approximately
80 up to 1,000 mg/day, corresponding to 1.4–18 mg/kg of body weight/
day (5). Acrylamide and glycidamide, its epoxide metabolite, are
genotoxic and may potentially act as endocrine-disrupting chemicals,
thereby altering physiologic hormonal balance at lower doses com-
pared with exposure levels in occupational studies (14–17). In par-
ticular, acrylamide intake is associated with alteration of sex hormone
levels in both pre- and postmenopausal women (18, 19), mainly
increasing estradiol and follicle-stimulating hormone levels (19). Its
association with hormone-dependent gynecologic neoplasms has been
investigated previously. Many epidemiologic studies on acrylamide
exposure (assessed either through diet or hemoglobin adducts) and
breast and gynecologic cancers have been published, but few system-
atic reviews have addressed this topic (20–22). These reviews tend to
report small increases in risk of endometrial and ovarian cancers,
especially in never-smoking populations, but null risk for breast
cancer. No dose–response meta-analysis has been performed previ-
ously. We conducted a dose–response meta-analysis based on
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epidemiologic studies of acrylamide dietary intake and risks of female
breast, endometrial, and ovarian cancer.
Materials and Methods
Literature search
We carried out a systematic literature PubMed/Medline database
search through February 25, 2020 using the entry terms acrylamide
and (cancer or neoplasm or tumor) and (dietary or diet or nutritional
or food) and (ovarian or ovary or endometrial or breast or mamma-
lian). After assessing the results, we limited our review to studies on
dietary exposure to acrylamide, with case–control or cohort designs,
and those studies that reported breast, endometrial, or ovarian cancer
risk estimates alongwith their 95% confidence intervals (CI) according
to acrylamide exposure (mg/day). We excluded nonepidemiologic
studies, studies not reporting risk estimates, and studies assessing
acrylamide exposure using hemoglobin adducts.
Data extraction
For each study, we abstracted country, design, cohort name, and
population characteristics including range of study years, follow-up
duration, total number andmean age of participants, number of cases,
and adjustment factors. We compiled data on acrylamide levels
divided into available categories (e.g., quantiles) and risk estimates.
When reported, we also abstracted data stratified for smoking status,
menopausal status, body mass index (BMI) category, and hormone
receptor status (breast cancers only).
Data analysis
We first conducted a meta-analysis of the overall measure of
association (risk ratio, RR; hazard ratio, HR; or odds ratio, OR;
hereafter reported as RR) and corresponding 95% CIs of each cancer
type by comparing the highest versus the lowest level of exposure in a
random effect model. In this analysis, we assessed heterogeneity by
reporting I2 statistics, and by carrying out stratified analyses.
We also performed a dose–response meta-analysis, implementing
the recently developed one-stage methodology (23, 24) that we have
applied previously (25–27), which allows the estimation of RRs across
a large range of acrylamide intake alongside with their approximate
point wise 95%CIs. For the exposure categories reported in each study,
we extracted themean ormedian depending on which was available. If
unavailable, we inputted in themodel themidpoint of each category or,
when the extreme boundaries for the highest and the lowest exposure
category were not reported, we entered a value 20% higher or lower
than the closest cutoff (28, 29). For this analysis, we used restricted
cubic splineswith three knots atfixed percentiles (10th, 50th, and 90th)
of exposure distribution using generalized least-squares regression
model (24). To do this we took into account the correlationwithin each
set of published RRs, and the study-specific estimates were combined
using multivariate random-effect meta-analysis through the restricted
maximum likelihoodmethod (23). For all studies, we alsofitted a linear
regression analysis model and reported its slope alongside with the
shape of the nonlinear relation yielded by the spline analysis (23).
In sensitivity analyses, we provided a graphical overlay of study-
specific predicted curves including fixed and random effects, display-
ing the influence of variation across studies (24). We also reran all
analyses by removing one study at a time to evaluate the specific
influence of the omitted study on the results, and to assess source and
magnitude of any heterogeneity. We performed all statistical analyses
using the “metan” and “drmeta” routines in the STATA Software
(version 16.1; StataCorp).
Results
In Fig. 1, we report overall results of our database search. We
retrieved 343 unique publications from online databases, which were
reduced to 22 based on title and abstract screening. We excluded four
studies for being conference abstracts (two studies, all followed by
eligible publications), a literature review, and a commentary, leaving 18
studies for the qualitative analysis. We report general characteristics of
included studies in Table 1. The most common study designs were the
cohort (11 studies; refs. 30–40) and case cohort (five studies;
refs. 7, 41–44), followed by two case–control studies (28, 29). These
studies were published between 2005 and 2019, and the vast majority
were carried out in Europe (n¼ 15), followed by the United States (n¼
2), and Japan (n¼ 1). Some studies assessedmore than one cancer type.
Overall, 10 studies assessed breast cancer (28, 30–35, 42, 44), seven
endometrial cancer (7, 29, 35–37, 40, 43), and seven ovarian can-
cer (7, 28, 35, 36, 38, 39, 41), with a total of 18,100, 3,561, and 3,569 cases
of breast, endometrial, and ovarian cancer, respectively. Acrylamide
dietary intake ranged from3.6mg/day to 44mg/day, with bothmean and
median values of 21 mg/day (range 6.3–29.8 mg/day). All but three
studies reported risk estimates among never-smoking wom-
en (28, 33, 39), while six carried out stratified analysis according to
menopausal status (29–31, 35–37) or recruited either pre- (34) or
postmenopausal women only (7, 32, 40, 41, 43). Finally, five studies
presented results stratified by BMI (i.e., <25 and ≥25 kg/m2;
refs. 29, 31, 35–37), and six studies on breast cancer stratified the
results by hormone receptor status, that is, estrogen receptor (ER) status
and/or progesterone receptor (PR) status (refs. 31, 32, 34, 35, 42, 44;
Supplementary Table S1). Five reports were available on the same
study population (7, 41–44), and in these cases we included only the
most recent and complete papers in our analyses (41–43).
In the meta-analysis summarizing the RR in the highest category of
exposure versus the lowest, we found little evidence of any change in
cancer risk at higher levels of acrylamide exposure, with a summary RR
(sRR) of 0.96 (95%CI, 0.91–1.02) for breast cancer, 1.03 (95%CI, 0.91–
1.17) for endometrial cancer, and 1.01 (95% CI, 0.87–1.18) for ovarian
cancer (Table 2; Supplementary Fig. S1). All summary estimates were
statistically imprecise. Restricting the analysis to never smokers, we
observed similar results for breast cancer, but stronger although
statistically imprecise risks for endometrial and ovarian cancer (sRR,
1.14; 95% CI, 0.96–1.36 and sRR, 1.17; 95% CI, 0.79–1.72,
respectively; Table 2; Supplementary Fig. S2). In analyses stratified
by menopausal status (Table 2; Supplementary Fig. S3), we found no
appreciable association between exposure and risk of breast cancer
among premenopausal women, and an inverse association in post-
menopausal participants. Regarding endometrial cancer, we found
lower risk among premenopausal women and a slightly higher risk
among postmenopausal with higher exposure, although associations
were imprecise. Ovarian cancer showed a positive association
with acrylamide exposure among premenopausal women, although
these findings were based on only two studies reporting opposite
results (35, 36), while there was little evidence of increased risk among
postmenopausal women. Results among never-smoking premeno-
pausal women were available only for one study, which reported a
positive association between acrylamide exposure and breast cancer
risk (30). Conversely, among postmenopausal women, we found no
association for breast cancer, and positive associations between acryl-
amide exposure and both endometrial and ovarian cancers (Table 2;
Supplementary Fig. S4).
After stratifying analyses by BMI, we observed statistically
imprecise, slightly positive associations between acrylamide intake
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and risk of endometrial and ovarian cancers only among women
with BMI <25 kg/m2 (Table 2; Supplementary Fig. S5). When
stratifying for hormonal receptor status, we did not detect sub-
group-specific changes in risk (Table 2).
In the dose–response meta-analysis, we found little association
between dietary acrylamide intake and breast cancer risk, but
rather some evidence of a slight inverse relation among never
smokers (Fig. 2). For endometrial cancer, risk slightly increased for
increasing exposure until the intermediate levels of exposure. At
the highest levels of intake, risk tended to decrease among women
overall, but remained constant in never smokers. Acrylamide
intake was positively associated with risk of ovarian cancer,
although at levels above 20 mg/day of acrylamide, the slope
attenuated. Analyses restricted to never-smoking women showed
the same pattern, but a higher risk at the corresponding levels of
exposure (Fig. 2).
Dose–response analyses by menopausal status showed different
patterns of association. Among premenopausal women, risk started to
increase from approximately 20 mg/day of acrylamide intake for breast
cancer in a linear manner, while the association was inverse and linear
among postmenopausal women (Supplementary Figs. S6 and S7). The
graph of the association between exposure and endometrial cancer did
not suggest clear evidence of association and trends. The number of
ovarian cancer studies was too few to carry out a dose–response
analysis. Among postmenopausal women, increasing acrylamide
intake was associated with greater breast cancer risk until 20 mg/day
of exposure, after which the relation flattened (Supplementary Fig. S6).
Because of the small number of studies, no dose–response meta-
analysis by menopausal status among never-smokers could be
performed.
In general, we found some heterogeneity in results between studies
(Table 2). Conversely, whenwe reported study-specific dose–response
Figure 1.
Flowchart of literature search and identification through February 25, 2020.
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trends (Supplementary Fig. S8), we foundmoderate variation in results
for endometrial cancer only, while breast and ovarian cancers dem-
onstratedmore comparable study-specific dose–response trends. After
systematically removing each study in turn from the analyses, we
observed no appreciable change in summary estimates (Supplemen-
tary Figs. S9–S29). Among never smokers, results for breast and
endometrial cancers were similar (Supplementary Figs. S12 and
S13), while risk of ovarian cancer showed an inverse association
after removing one study (ref. 41; Supplementary Fig. S14). Funnel
plots showed substantial symmetric distributions for all cancer types
(Supplementary Fig. S30), with little indication of any publication bias.
Discussion
We observed that acrylamide intake was associated with small
increased risks of endometrial and ovarian cancer, with stronger and
almost linear associations among never smokers. However, no positive
relation emerged for breast cancer, except among premenopausal
women for exposure above 20 mg/day. Data were too limited to
examine endometrial and ovarian cancers by menopausal status with
reasonable precision. In the literature, studies of glycidamide hemo-
globin adducts have been conflicting, with a positive association
observed in a European population (45) and no association in a
comparable U.S. study (46). Conversely, hemoglobin adducts of
acrylamide and glycidamide showed little association with endome-
trial cancer risk in a recent cohort-nested case–control study (47).
To the best of our knowledge, this is the first systematic review
examining the shape of the dose–response relation of dietary acryl-
amidewith breast and gynecologic cancers. In addition, we updated the
previous meta-analysis of cancer risk associated with acrylamide
exposure (one including all cancers overall and one endometrial cancer
only; refs. 20, 21) by adding six newly published studies, two studies
each for breast (31, 44), endometrial (36, 43), and ovarian can-
cer (36, 41). Previous meta-analyses reported a slight increase in risk
of endometrial and ovarian cancer at high levels of acrylamide intake,
primarily among never smokers, and no association for breast cancer.
In a nested case–control study evaluating acrylamide exposure
through hemoglobin adduct concentration, higher exposure levels
were positively associated with breast cancer risk, particularly among
ERþ women (48), although these results were opposite to those
generated by a recent case–cohort study (44). In addition, in a cohort
study evaluating exposure to air pollutants and breast cancer risk,
ERþ/PRþ cancers were associated with higher ambient concentrations
of acrylamide (49), a finding consistent with observations from a
Table 2. Summary risk ratios (RRs) for the association of breast, endometrial, and ovarian cancer riskwith acrylamide intake comparing
the highest versus the lowest exposure categories for overall study population and restricted to never-smoking women.
All women Never-smoking women
n RR (95% CI) I2 (%) n RR (95% CI) I2 (%)
Breast cancer
All studies 8 0.96 (0.91–1.02) 0.0 6 0.92 (0.84–1.00) 0.0
Menopausal status
Premenopausal 4 1.02 (0.85–1.21) 38.5 1 1.17 (0.69–2.00) —
Postmenopausal 5 0.93 (0.87–1.00) 0.0 3 1.02 (0.85–1.23) 0.0
BMI
<25 kg/m2 2 0.93 (0.83–1.03) 0.0
≥25 kg/m2 2 0.97 (0.87–1.08) 0.0
Hormone receptor status
ERþ 3 0.90 (0.74–1.10) 0.0 1 1.31 (0.87–1.97) —
ER 2 0.87 (0.60–1.27) 0.0 1 0.95 (0.52–1.72) —
PRþ 2 1.02 (0.77–1.36) 0.0 1 1.47 (0.86–2.51) —
PR 2 0.84 (0.61–1.16) 0.0 1 0.84 (0.63–1.56) —
ERþPRþ 5 0.98 (0.89–1.08) 0.0 1 1.43 (0.83–2.46) —
ERPR 5 0.89 (0.78–1.02) 0.0
ERþPR 2 1.09 (0.89–1.33) 0.0
ERPRþ 1 1.09 (0.63–1.88) —
Endometrial cancer
All studies 6 1.03 (0.91–1.17) 0.0 6 1.14 (0.96–1.36) 0.0
Menopausal status
Premenopausal 5 0.89 (0.62–1.29) 43.4 — — —
Postmenopausal 5 1.05 (0.88–1.25) 0.0 2 1.31 (0.95–1.82) 0.0
BMI
<25 kg/m2 4 1.25 (0.73–2.13) 73.4
≥25 kg/m2 4 0.98 (0.76–1.25) 12.6
Ovarian cancer
All studies 6 1.01 (0.87–1.18) 25.9 4 1.17 (0.79–1.72) 49.5
Menopausal status
Premenopausal 2 1.15 (0.51–2.60) 41.2 — — —
Postmenopausal 4 1.05 (0.82–1.33) 33.2 2 1.41 (0.75–2.63) 56.8
BMI
<25 kg/m2 2 1.25 (0.57–2.73) 78.0
≥25 kg/m2 2 0.78 (0.49–1.24) 0.0
Abbreviations: BMI, body mass index; ER, estrogen receptor; I2 (%), heterogeneity; n, number of studies; PR, progesterone receptor.
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case–cohort study by Hogervorst and colleagues based on dietary
intake assessment (44). There is also evidence that acrylamide intake
might alter levels of estrogens in premenopausal women, although two
studies on this topic found opposite relations between dietary acryl-
amide intake and free estradiol levels (18, 19).
There is some biological plausibility for an association between
acrylamide exposure and both breast and gynecologic cancers. Female
rats exposed to high amounts of acrylamide had an increased incidence
of breast adenocarcinomas and fibroadenomas (50–52), similarly to
B6C3F1 mice and F344/N rats exposed to glycidamide through
drinking water (53, 54). A study conducted on MCF10A human
mammary cells confirmed their susceptibility to the toxicity of the
acrylamide epoxide metabolite, glycidamide (55). Concerning endo-
metrial cancer, glycidamide exposure induced uterine adenocarcino-
ma of the uterus and endometrial hyperplasia in female rats, and ovary
cancer in mice (52, 54). In addition, acrylamide may induce genotoxic
and cytotoxic effects through induction of oxidative imbalance (13)
leading to cell death or neoplastic transformation (56), and can alter
protein functions by binding to cysteine residues in proteins (22).
Acrylamide might also have endocrine disrupting properties (5).
Finally, glycidamide may alkylate DNA leading to point mutations
and potential activation of oncogenes or tumor suppressor
genes (57–59). Despite these findings in experimental animals, it is
uncertain whether usual exposure to glycidamide in the general
population may affect risk of gynecologic cancers, because its carci-
nogenicity may occur only at high doses (58). Specifically, in animal
studies, the acrylamide dose may be as high as 9.5 mg/kg of body
weight/day, a much higher exposure amount compared with that
characterizing the human studieswe considered, inwhichmedian level
was 21 mg/day (corresponding to 0.3 mg/kg of body weight/day, range
0.05–0.63; refs. 51, 53). Similarly, for acute occupational exposure,
acrylamide doses up to 18 mg/kg of body weight/day have been
reported (5). We found different results between all women and
never-smoking women, with stronger positive association for endo-
metrial and ovarian cancers (but not for breast cancer) in the latter,
which might be linked to some interactions between acrylamide
exposure and smoking. In fact, smoking has antiestrogenic
properties (60–62), and may alter acrylamide and glycidamide metab-
olism, thus modifying the association between acrylamide exposure
and cancer risk (63).
A major strength of our review is the implementation of a newly
developed biostatistical method to perform dose–response meta-anal-
ysis, allowing us to assess the shape of the relation between acrylamide
intake with cancer risk over a wide range of exposure. In addition, we
accounted for major established or putative risk factors such as body
weight, smoking habits, hormone replacement therapy/oral con-
traceptive use, lack of physical activity, and alcohol intake (64–67)
by using the most adjusted estimates from included studies. However,
we acknowledge that unmeasured confounding may still have influ-
enced these findings, with reference to environmental risk factors such
Figure 2.
Dose–response meta-analysis between
acrylamide intake and risk of breast (A;
refs. 28, 30–35, 42), endometrial (B;
refs. 29, 35–37, 40, 43), and ovarian cancer
(C; refs. 28, 36, 38, 39, 41) in all women, and
with breast (D; refs. 30–32, 34, 35, 42), endo-
metrial (E; refs. 29, 35–37, 40, 43), and
ovarian cancer (F; refs. 36, 38, 39, 41) in
never smokers. Spline curve (solid line) with
95% confidence limits (long-dashed lines),
null association (short-dashed line), and lin-
ear trend (vertical bar line). RR, risk ratio.
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as cadmium (68–70), pesticides (71–73), or air pollution (74–77).
Moreover, food frequency questionnaires used for acrylamide intake
estimation in the included studies did not generally collect information
about cookingmethods, potentially affecting the reliability of exposure
assessment (78) and contributing to heterogeneity in results.
In conclusion, although some results were based on a small
number of studies, our findings appear to support the currently
ongoing efforts to monitor and minimize acrylamide intake (79–82)
given some evidence of a small positive association with risks of
endometrial and ovarian cancer, particularly among never smokers.
Conversely, there was limited evidence for an association between
acrylamide intake and breast cancer risk, with the exception of
increased risks at ≥20 mg/day of acrylamide among premenopausal
women.
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